News
Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback